Cited by 150Colorectal Cancer Surgical TreatmentsColorectal Cancer Treatments and StudiesColorectal Cancer Screening and Detection

Completion of therapy by Medicare patients with stage III colon cancer

Open access
Dobie, Sharon A., Baldwin, Laura-Mae, Dominitz, Jason A., Matthews, Barbara, Billingsley, Kevin, Barlow, William·2006·JNCI: Journal of the National Cancer Institute

Abstract

BACKGROUND: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. METHODS: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer resection. We defined a measure of adjuvant chemotherapy completion as one chemotherapy administration claim in a month. We tested the validity of the created measure and its relation to 3-year cancer mortality adjusted for demographic, clinical, and environmental variables. We explored the association of patient characteristics and treating physician characteristics with chemotherapy completion by use of multivariable logistic regression modeling. RESULTS: Of the 3193 patients, 2497 (78.2%) completed the course. Risk of cancer-related mortality was statistically significantly lower among those completing chemotherapy (relative risk = 0.79, 95% confidence interval = 0.69 to 0.89) than those with no adjuvant therapy. Patients who were female, widowed, increasingly elderly, rehospitalized, and living in certain regions were less likely to complete adjuvant chemotherapy than other patients. Race and other clinical, environmental, and physician characteristics were not associated with completion of therapy. CONCLUSIONS: Factors associated with incomplete adjuvant chemotherapy may represent physical frailty, treatment complications, and lack of social and psychological support. Interventions to mitigate these influences are a logical next step toward increasing chemotherapy completion rates.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djj159

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. Wolmark N, Rockette H, Mamounas EP, Jones J, Petrelli N, Atkins J. The relative effi cacy of 5-FU+leucovorin (FU-LV), 5-FU+levamisole (FU-LEV) and 5-FU+leucovorin+levamisole (FU-LV-LEV) in patients with Ducke's B and C carcinoma of the colon: fi rst report of NSABP C-04 Proc ASCO 1996 ;15:205.
  2. Jessup JM, McGinnis LS, Steele GD Jr, Menck HR, Winchester DP. The National Cancer Data Base. Report on colon cancer. Cancer 1996 ; 78 : 918 -26.
  3. Dominitz JA, Samsa GP, Landsman P, Provenzale D. Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer 1998 ; 82 : 2312 -20.
  4. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fl uorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995 ; 75 : 11 -7.
  5. Bower M, Asbury R, Kramer Z, Pandya K, Bennett JM. Adjuvant chemo- therapy for colorectal cancer in the elderly: population-based experience. Proc ASCO 1993 ; 12 : 195 (Abs #570) .

Cited by

Sorted by citations

Authors
Dobie, S. A., Baldwin, L.-M., Dominitz, J. A., Matthews, B., Billingsley, K., & Barlow, W.
Affiliations
Oregon Health & Science University (US)
Corresponding author
Dobie, Sharon A.
Venue
JNCI: Journal of the National Cancer Institute
Published
2006-05-03
Volume
98
Issue
9
Pages
610-619
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2108822192
Cited by
150
References
53
Citations by year
2026: 2 · 2024: 5 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 13 · 2013: 11 · 2012: 11
FWCI
5.74
Type
journal article
Language
en
Open access
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R01CA089544)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
Keywords
stage III colon cancer, adjuvant chemotherapy, chemotherapy completion, Medicare beneficiaries, cancer mortality, predictors of treatment completion, patient characteristics, physician characteristics, SEER, Medicare claims data
MeSH terms
Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Female, Medicare, Humans, Male, Neoplasm Staging, Patient Compliance, Predictive Value of Tests, Risk Factors, Social Support, United States, Reproducibility of Results, Logistic Models, Frail Elderly, Chemotherapy, Adjuvant, SEER Program

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review